EPRX vs ESPR

Eupraxia Pharmaceuticals Inc. vs Esperion Therapeutics, Inc. — Valuation Comparison 2026

EPRX

Pharmaceutical Preparations
Eupraxia Pharmaceuticals Inc.
Quality
1.9
out of 10
Value Trap
6
SAFE
Price
$7.09
Last close
Models
7/13
Active
VS

ESPR

Pharmaceutical Preparations
Esperion Therapeutics, Inc.
Quality
5.2
out of 10
Value Trap
30
LOW
Price
$3.13
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType EPRX Fair ValueEPRX Upside ESPR Fair ValueESPR Upside
Bayesian DCF Intrinsic $1.82 -74.3% $1.10 -65.0%
First Chicago Scenario $9.92 +44.3% $6.15 +96.5%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $4.13 -41.8% $5.57 +78.1%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EPRX vs ESPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EPRX vs ESPR — Which Stock Is More Undervalued?

ESPR scores higher with a 5.2/10 quality rating vs EPRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Eupraxia Pharmaceuticals Inc. (EPRX) and Esperion Therapeutics, Inc. (ESPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EPRX currently trades at $7.09 with a QOC of 1.9/10, while ESPR trades at $3.13 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).